Procept secures FDA IDE for Aquablation and completes WATER IV study enrolment

Procept BioRobotics has received a second FDA IDE to allow another randomised study of its Aquablation therapy. Procept BioRobotics anticipates sharing the primary endpoint results from WATER IV in 2027. The WATER IV AS trial aims to assess Aquablation as earlier intervention for men on active surveillance, with ten-year follow-up. Credit: PROCEPT BioRobotics Corp. / GlobeNewswire. Procept BioRobotics has received a second FDA investigational device exemption (IDE) to allow another randomised study of its Aquablation therapy. The regulatory clearance permits the start of a study comparing Aquablation therapy to active surveillance in men with Grade Group 1 and 2 prostate…

Source: Medical Device Network